Replies to post #147987 on Anavex Life Sciences Corp (AVXL)

[OFP]

“Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials.”

This is quite a dramatic statement - do we interpret this statement that patients with these signature will benefit from A2-73 such that it will have positive impact on Alz?

If they PR it officially - it will be big news and lot of questions as to veracity of this claim

I think you've hit on the problem of "questions of veracity". They can PR all they want. It is unknowable, patently absurd, and is just fodder for the ignorant.

[XenaLives]

It will be disclosed at a scientific conference as they have been saying for months.

do we interpret this statement that patients with these signature will benefit from A2-73 such that it will have positive impact on Alz?

No, better than that. I interpret it as enabling the company to hit consecutive bull's eyes in trials. This will lower cost and duration. I expect that there will be positive results (doesn't take much to beat BP's record) for those out of the bulls eye but homing in on that bulls eye will make trials less expensive and shorter in duration.

They will PR it offically - after accepted by FDA with substantial clinical justification.